AzTrials
AzTrials

Heart Transplant FailureDCDNRPHeartNCT04626284

Safety and Effectiveness of NRP for DCD Heart Transplantation

A study testing Heart Transplantation in people with Heart Transplant Failure and Determination of Death, run by University of Nebraska at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This is a prospective, observational, pilot trial to evaluate the feasibility of heart transplantation using normothermic regional perfusion (NRP) donation after donor circulatory death (DCD). Read more about this study

Who is it for?
Ages 19 years and older
What is being tested?
Heart Transplantation
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
10 participants
Where
1 siteUnited States
Study dates
3 Jan 2021to 8 Apr 2022
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Recipient is ≥ 19 years old
  • Recipient, or their designated healthcare proxy, is able and willing to sign informed consent
  • Recipient meets standard listing criteria for heart transplantation

Who cannot join

  • Recipient is < 19 years old
  • Recipient, or their designated healthcare proxy, is unable to sign informed consent
  • Recipient is participating in another interventional trial
  • Recipient has a known history of HIV infection
  • Recipient has any condition that, in the opinion of the Investigator, would make study participation unsafe or would interfere with the objectives of the study

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Nebraska Medical Center

    Omaha, Nebraska, 68198

Other trials in United States

About this study

Official title: Clinical Trial to Evaluate the Safety and Effectiveness of Normothermic Regional Perfusion (NRP) for Resuscitation of Hearts From Donation After Circulatory Death (DCD)

This is a prospective, observational, pilot trial to evaluate the feasibility of heart transplantation using normothermic regional perfusion (NRP) donation after donor circulatory death (DCD). Normothermic regional perfusion utilizes Extracorporeal Membrane Oxygenation (ECMO) or cardiopulmonary bypass to reperfuse the heart and other organs in situ after isolation and ligation of the cerebral vessels. In situ resuscitation of the heart has the added advantage of allowing full hemodynamic and echocardiographic assessment of the donor heart prior to final acceptance for transplantation without the imminent danger of ongoing warm ischemia.

Read the detailed description

The current procedure of DCD organ donation and procurement follows a well-established course for lung, liver, kidney and pancreas transplantation in the United States. DCD transplantation of a heart has been hampered due to concern about the graft viability after the obligatory period of warm ischemia and also the limited ability to assess the graft function after the cessation of circulation. Normothermic regional perfusion restores the circulation and enables in-situ reanimation of thoracic and abdominal organs after the circulatory determination of death. For heart transplantation, the investigators will accept donors between the ages of 18 and 49 without any known history of coronary artery disease, insulin dependent diabetes, or long-term smoking (>20 pack/years) and normal baseline cardiac function (EF>50) assessed with transthoracic echocardiogram. After the authorization for research has been obtained from DCD surrogate, the organs will be allocated through UNOS. When all parties are present and ready, the donor will be withdrawn from life support (i.e., discontinuation of mechanical ventilation and any vasoactive medications). . After circulatory arrest occurs, death is declared by a physician not associated with the transplant teams. Subsequently a period of stand-off is observed (5 minutes for organs donated in Nebraska) to ensure complete cessation of the circulation before organ procurement is commenced. If after withdrawal of life support the patient does not progress to circulatory death within the allotted time, the procurement is abandoned and the patient is transferred out of the operating room and placed on palliative measures.

Given that DCD organ donation is already currently practiced in the US, the same standard approach defined by each state and locality can also be applied to DCD heart donation and will be followed for this protocol at UNMC. However, this protocol will utilize a normothermic regional perfusion (NRP) strategy that involves reestablishment of circulatory blood flow after the period of circulatory arrest has been established and the 5 minutes of standoff time has passed. The local Organ Procurement Organization (LiveOnNE) have reviewed and approved this approach to DCD heart donation. Specifically, normothermic regional perfusion involves the following steps:

  1. Opening the chest through a standard sternotomy used for heart and lung procurement.
  2. Ligation of the all the blood vessels that supply blood to the brain to ensure that blood flow to the brain is not reestablished once circulation is restarted as described below.
  3. Standard cannulation of the aorta and the right atrium as is done for cardiac surgical procedures.
  4. Initiation of cardiopulmonary bypass, which will re-establish the flow of blood to all organs of the body including the heart under normothermia. The initial step for ligation of the blood vessels to the head is necessary to ensure that blood flow to the brain does not occur.

Once blood flow to the heart is established, the heart will start beating. At 30 minute intervals, the donor will be separated from cardiopulmonary bypass and the heart will be assessed for functionality. If accepted standard DBD procurement will commence. The heart transplantation surgery on the potential recipient will only begin once the heart has been accepted as suitable.

If after assessment the heart is not suitable, cardiopulmonary bypass will be restarted. The donor heart will be reassessed at 30-minute intervals up to 180 minutes. If no significant acceptable recovery occurs and the heart is not deemed suitable for transplantation, then the study will be terminated, but the remaining organs can be recovered as standard practice.

Being tested
Heart Transplantation
Keywords
Heart transplantation, Donation after circulatory death, Normothermic regional perfusion
Medical subject headings
Death

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Heart TransplantationProcedure or surgery

    Heart Transplantation

Study groups in NCT04626284
Study groupRoleWhat they receive
Donors After Circulatory Determined deathExperimentalRecipients receiving an organ from donors after circulatory determined death
Receives: Procedure: Heart Transplantation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Utilization rate

    Ratio of successful heart transplants using grafts obtained from DCD donors using NRO to the total number of DCD donors in whom NRP was used to procure an organ

    Measured: Date from the first DCD NRP Heart procurement until the 25th DCD NRP heart procurement, assessed up to 36 months

Secondary outcomes (4)
  1. Graft survival

    Survival of the graft censored either at the time of death of the recipient or retranaplantation

    Measured: From date of the transplantation to date of death or retransplantation, whichever comes first, assessed up to 12 months

  2. Primary Graft Dysfunction (PGD)

    Primary Graft Dysfunction as defined by ISHLT

    Measured: From day of heart transplantation up to 72 hours post-transplantation

  3. Acute cellular rejection (ACR)

    Biopsy proven acute cellular rejection requiring treatment

    Measured: From day of heart transplantation up to 1 year post-transplantation

  4. Antibody mediated rejection (AMR)

    Biopsy proven antibody mediated rejection

    Measured: From day of heart transplantation up to 1 year post-transplantation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Nov 2020
  2. Study start3 Jan 2021
  3. Primary completion8 Apr 2022
  4. Study completion8 Apr 2022

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
10 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04626284
Sponsor's protocol ID
0460-20-FB
Acronym
DCDNRPHeart
Status last verified
Sep 2023
First submitted
2 Nov 2020
Last updated
28 Sep 2023
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Barnard CN. The operation. A human cardiac transplant: an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town. S Afr Med J. 1967 Dec 30;41(48):1271-4. No abstract available.

    PubMed 4170370
  • Dhital KK, Chew HC, Macdonald PS. Donation after circulatory death heart transplantation. Curr Opin Organ Transplant. 2017 Jun;22(3):189-197. doi: 10.1097/MOT.0000000000000419.

    PubMed 28379853
  • Messer S, Page A, Colah S, Axell R, Parizkova B, Tsui S, Large S. Human heart transplantation from donation after circulatory-determined death donors using normothermic regional perfusion and cold storage. J Heart Lung Transplant. 2018 Jul;37(7):865-869. doi: 10.1016/j.healun.2018.03.017. Epub 2018 Mar 30.

    PubMed 29731238
  • Chew HC, Iyer A, Connellan M, Scheuer S, Villanueva J, Gao L, Hicks M, Harkness M, Soto C, Dinale A, Nair P, Watson A, Granger E, Jansz P, Muthiah K, Jabbour A, Kotlyar E, Keogh A, Hayward C, Graham R, Spratt P, Macdonald P, Dhital K. Outcomes of Donation After Circulatory Death Heart Transplantation in Australia. J Am Coll Cardiol. 2019 Apr 2;73(12):1447-1459. doi: 10.1016/j.jacc.2018.12.067.

    PubMed 30922476

Questions about this trial

What is this clinical trial studying?

A study testing Heart Transplantation in people with Heart Transplant Failure and Determination of Death, run by University of Nebraska at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Sep 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Utilization rate (time frame: Date from the first DCD NRP Heart procurement until the 25th DCD NRP heart procurement, assessed up to 36 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04626284, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Sep 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in